免疫系统是机体维持正常生理功能的重要系统,多种免疫细胞表面的程序性死亡受体-1(programmed cell death protein 1,PD-1)及其配体程序性死亡配体-1(programmed cell death-ligand 1,PD-L1)是重要的共抑制分子,在病理状态下能够传递免...免疫系统是机体维持正常生理功能的重要系统,多种免疫细胞表面的程序性死亡受体-1(programmed cell death protein 1,PD-1)及其配体程序性死亡配体-1(programmed cell death-ligand 1,PD-L1)是重要的共抑制分子,在病理状态下能够传递免疫抑制信号,导致T细胞失能,从而引发免疫系统的功能障碍。研究表明,PD-1/PD-L1通路通过调控相关细胞因子及多种下游信号等方式,在多种疾病发生发展过程中发挥重要作用。论文对PD-1/PD-L1的结构、表达调控、作用机制及其在微生物、寄生虫等病原感染中作用的研究进展进行总结分析,以期为深入研究和揭示PD-1/PD-L1在疾病发生,特别是在病原微生物感染中的作用及相关疾病的防治提供基础资料。展开更多
1 文献来源Wu YL,Zhang L,Fan Y,et al.Randomized clinical trial of pembrolizumab vs chemotherapy for previously untreated Chinese patients with PD-L1-positive locally advanced or metastatic non-small-cell lung cancer:KE...1 文献来源Wu YL,Zhang L,Fan Y,et al.Randomized clinical trial of pembrolizumab vs chemotherapy for previously untreated Chinese patients with PD-L1-positive locally advanced or metastatic non-small-cell lung cancer:KEYNOTE-042 China Study [J].Int J Cancer,2021,148(9):2313-2320.2 证据水平1b。展开更多
1 文献来源Borghaei H,Langer CJ,Paz-Ares L,et al.Pembrolizumab plus chemotherapy versus chemotherapy alone in patients with advanced non-small cell lung cancer without tumor PD-L1 expression:A pooled analysis of 3 rand...1 文献来源Borghaei H,Langer CJ,Paz-Ares L,et al.Pembrolizumab plus chemotherapy versus chemotherapy alone in patients with advanced non-small cell lung cancer without tumor PD-L1 expression:A pooled analysis of 3 randomized controlled trials [J].Cancer,2020,126(22):4867-4877.2 证据水平1b。展开更多
文摘免疫系统是机体维持正常生理功能的重要系统,多种免疫细胞表面的程序性死亡受体-1(programmed cell death protein 1,PD-1)及其配体程序性死亡配体-1(programmed cell death-ligand 1,PD-L1)是重要的共抑制分子,在病理状态下能够传递免疫抑制信号,导致T细胞失能,从而引发免疫系统的功能障碍。研究表明,PD-1/PD-L1通路通过调控相关细胞因子及多种下游信号等方式,在多种疾病发生发展过程中发挥重要作用。论文对PD-1/PD-L1的结构、表达调控、作用机制及其在微生物、寄生虫等病原感染中作用的研究进展进行总结分析,以期为深入研究和揭示PD-1/PD-L1在疾病发生,特别是在病原微生物感染中的作用及相关疾病的防治提供基础资料。
文摘1 文献来源Wu YL,Zhang L,Fan Y,et al.Randomized clinical trial of pembrolizumab vs chemotherapy for previously untreated Chinese patients with PD-L1-positive locally advanced or metastatic non-small-cell lung cancer:KEYNOTE-042 China Study [J].Int J Cancer,2021,148(9):2313-2320.2 证据水平1b。
文摘1 文献来源Borghaei H,Langer CJ,Paz-Ares L,et al.Pembrolizumab plus chemotherapy versus chemotherapy alone in patients with advanced non-small cell lung cancer without tumor PD-L1 expression:A pooled analysis of 3 randomized controlled trials [J].Cancer,2020,126(22):4867-4877.2 证据水平1b。
